Canadian-based Aurora Cannabis has now received EU-GMP for its medical cannabis production facility in Germany.
Aurora has stated that the certification marks a significant milestone in the fulfilment of an awarded tender by the German Federal Institute for Drugs and Medical Devices (BfArM).
The company’s new state-of-the-art production facility in Leuna, Saxony-Anhalt, Germany adds to its pan-European network of EU-GMP facilities supplying medical cannabis flower and extracts for patients.
Read more: Aurora fulfils first shipment for French medical cannabis programme
CEO of Aurora Cannabis, Miguel Martin, commented: “With the EU-GMP certification of our first German site, we once again demonstrate Aurora’s excellence and leadership in establishing the necessary infrastructure to compete in the global cannabis market.
”As a leading provider of medical cannabis in Germany and several other European markets, we are eager to accelerate patient access to high-quality, reliable cannabis produced in accordance with the most stringent criteria.
“Our first shipment from our world-class Leuna facility will deliver on our commitment to the German regulatory authority and expanding patient base, a significant step in our ongoing commitment to international market growth.”
Read more: Roundup of Q1 2022 financial results in the UK medical cannabis space
Aurora was awarded a contract in 2019 by the German Federal Institute for Drugs and Medical Devices (BfArM) for the annual production of 1,000 kg of high-quality medical cannabis flower over a period of four years.
The Aurora Leuna is a nearly 3,600 sq. metre production site and, now completed, is preparing for the inaugural shipment. The first shipment from Aurora Leuna to German pharmacies is expected via the state’s cannabis agency later this month.
Martin continued: “As a leading provider of cannabis flower and extracts in Germany, we are excited by the possibility of growth in the market. Our investment in domestic production with the highest quality standards will help advance patient access to high-quality cannabis.
“I congratulate our team in Germany on achieving this important milestone for our Leuna facility and the commencement of local production in this critical market.”
[activecampaign form=31]
